65 results about "Bacteroides salyersiae" patented technology

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention relates to heparinase III with high activity on 6-sulfated heparin and application of the heparinase III. The amino acid sequence of the heparinase III (BeHepIII) is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. The invention discovers and discloses a novel heparinase III (BeHepIII) for the first time, the heparinase III is derived from Bacteroides eggerthii, has a higher recombinant expression level in escherichia coli, has very high degradation activity on heparin containing a 6-site sulfated structure, and particularly has the enzyme activity which is 93.5 times of that of commercialized heparinase FhHepIII at present, and the heparinase III can be used for degrading heparin containing 6-site sulfated structure. Therefore, the heparinase III (BeHepIII) provided by the invention has a wide application potential in heparin degradation. In addition, by using heparinase III (BeHepIII), directional excision of a reducing end of heparin oligosaccharide synthesized by a chemical enzyme method is realized, and complete chemical enzyme method synthesis of a pentasaccharide structure with anticoagulant factor Xa activity is successfully realized.

The invention discloses a meningioma enteric microbial marker, a product and application of the meningioma enteric microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and is characterized in that the enteric microbial marker comprises one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and the enteric microbial marker comprises one or more of parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

The present invention provides a compound of Formula (I), which can be used to prepare a composition for losing weight and improving gut microbiota composition. The invention also provides a composition comprising an effective amount of the compound, which has the ability to increase the abundance of Bacteroidales, thereby reducing the ratio of Firmicutes to Bacteroidetes, and can increase the abundance of beneficial gut bacteria and change the gut microbiota composition. The compound and composition of the invention can be applied in food, medicine, feed, nutritional supplements and other uses.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

The invention relates to the technical field of biomedicine, and discloses application of bacteroides sailli as a biomarker in preparation of sepsis diagnosis and / or prognosis evaluation products. The kit for the auxiliary diagnosis of the sepsis comprises a reagent for detecting the bacteroides sailli (Bacteroides sailli), and the reagent is used for detecting the bacteroides sailli (Bacteroides sailli). As a detection variable of sepsis, the single bacterium of Bacteroides sailli has high specificity and sensitivity, can be applied to diagnosis of sepsis patients as a detection marker, is high in accuracy, provides an intestinal flora detection means for the sepsis patients, provides a bacterium source basis for judging sepsis and intestinal flora disorder of the patients according to the intestinal flora detection means, and has a good application prospect. And a basis is provided for later-stage intestinal bacteria transplantation.

To provide a composition that increases the occupancy rate of bacterium of the genus Parabacteroides and bacterium of the genus Bifidobacterium in intestinal flora.SOLUTION: A composition for improving intestinal flora is provided, the composition containing any one material selected from trehalulose, isomaltulose, turanose, maltulose, and oligosaccharides containing any one material from these materials as a constituent sugar.SELECTED DRAWING: Figure 1

The invention discloses a primer composition for detecting bifidobacterium bifidum of which the microbial preservation number is CCTCC (China Center for Type Culture Collection) NO: M2023349, enterococcus avium of which the microbial preservation number is CCTCC NO: M2023350, lactobacillus salivarius of which the microbial preservation number is CCTCC NO: M2023348, lactobacillus fermentum of which the microbial preservation number is CCTCC NO: M2023352, and parabacteroides didysonii of which the microbial preservation number is CCTCC NO: M20222033. The invention further discloses a kit based on the primer composition and application of the kit. The primer composition has good specificity and high accuracy aiming at the five bacteria, and can detect the five bacteria in a complex environment to evaluate the physiological status of a subject.

The present invention discloses a capsular polysaccharide extract of Bacteroides uniformis and its application in the prevention and treatment of ulcerative colitis. The Bacteroides uniformis extract is a capsular polysaccharide of Bacteroides uniformis. In the present invention, the inventors first discovered a capsular polysaccharide of Bacteroides uniformis and found that it can effectively prevent or treat DSS-induced colitis, and verified the effectiveness of this effect through a colitis mouse model, thus providing a new idea and means for the treatment of ulcerative colitis.

The invention discloses a kit for detecting intestinal core bacteria by a TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) method, and belongs to the technical field of kits. The kit disclosed by the invention comprises standard positive templates of nine common intestinal core bacteria and nine groups of specific primers and probes which are required in a PCR amplification process and correspond to the standard positive templates. The kit disclosed by the invention is simple, convenient and rapid to operate; the specificity is good and the sensitivity is high; complicated raw information data analysis does not need to be carried out; the intestinal core bacteria can be detected and quantified without high-throughput sequencing, and three bacteria can be detected in one reaction hole, so that the cost is greatly reduced. The kit provided by the invention can be used for rapidly and quantitatively detecting nine intestinal core bacteria including bifidobacterium, lactobacillus, prevotella, bacteroides and the like, can partially replace a high-throughput detection method which is higher in cost and more complicated to operate according to research and diagnosis purposes, and is suitable for being widely popularized in clinical detection and laboratory research.

The present invention relates to the application of creatmycin in inhibiting gastrointestinal tract pathogenic bacteria, and the gastrointestinal tract pathogenic bacteria include but are not limited to: Helicobacter pylori, Clostridium difficile, Bacteroides fragilis, Escherichia fergusonii, Clostridium sporogenes.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

The invention discloses a microecological preparation capable of regulating and controlling abundance of intestinal bifidobacteria in a targeted mode and application of the microecological preparation, the microecological preparation is composed of intestinal symbiotic bacteria and prebiotics, the intestinal symbiotic bacteria are bacteroides, and the prebiotics are polysaccharide containing N-acetylglucosamine. The prebiotics and the bacteroides multiforme CCFM1441 are combined for use, the prebiotics N-acetylglucosamine can be effectively released, nutrition is provided for bifidobacterium longum, and proliferation of the bifidobacterium longum is promoted. Further, in vitro and in vivo experiments prove that there is a strong cross-feeding activity between Bacteroides multiforme CCFM1441 and Bifidobacterium longum based on prebiotics. The beneficial microecological preparation can promote proliferation of bifidobacterium longum in intestinal tracts in a targeted manner, improves intestinal flora imbalance caused by antibiotics, and further has a huge application prospect in preparation of products (such as food, drugs or health care products) for improving intestinal health.

This invention belongs to the field of intestinal microbiome technology, and particularly relates to the application of a capsular polysaccharide derived from Bacteroides Salilsii CSP6 in the treatment and / or prevention of inflammatory bowel disease. The Bacteroides Salilsii strain is... Bacteroides salyersiae CSP6. This strain was isolated from the intestine of healthy humans and deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20221993. In vivo experiments showed that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can protect the colorectal mucosa from damage and promote the repair of damaged intestinal mucosa, thereby improving symptoms such as loose stools, rectal bleeding, and shortened colon and rectum, reducing weight loss caused by intestinal damage and inflammation, and ultimately exerting a therapeutic effect on inflammatory bowel disease.

Provided in the present invention is a probiotic. The probiotic includes Parabacteroides distasonis with the microbial deposit number of CCTCC NO: M20222033, Limosilactobacillus fermentum with the microbial deposit number of CCTCC NO: M2023352, Lactobacillus salivarius with the microbial deposit number of CCTCC NO: M2023348, Enterococcus avium with the microbial deposit number of CCTCC NO: M2023350, and Bifidobacterium bifidum with the microbial deposit number of CCTCC NO: M2023349. The probiotic has good safety, has antioxidant activity, can inhibit pathogenic bacteria, can alleviate colon injury, can inhibit inflammation, and can alleviate diarrhea caused by chemotherapeutic drugs.

The invention belongs to the technical field of natural medicines, and particularly provides an application of cynomorium songaricum total polysaccharide in any one or more of the following applications: (1) preparing a medicament for inhibiting parabacteroides dielsii P.disassonis; (2) preparing a medicament for preventing and / or treating chronic airway inflammatory diseases caused by parabacteroides dielsii; according to the invention, the relevance between the P.distasonis and the asthma is proposed for the first time, and a new target spot is provided for asthma treatment by inhibiting the P.distasonis; the new medicinal application of the cynomorium songaricum total polysaccharide is developed, the effect of the cynomorium songaricum total polysaccharide on inhibiting P.distans is utilized, the medicine capable of treating asthma is prepared, and the blank of targeted therapy of asthma aiming at the strain in the prior art is filled; the invention provides a new scheme different from the existing asthma treatment medicines, is expected to overcome the problems of systemic side effects or curative effect limitation and the like possibly caused by long-term use of the existing medicines, and provides a new choice for asthma treatment.

The invention discloses bacteroides vulgaris AF107-22 and an application of the bacteroides vulgaris AF107-22. The strain is preserved in Guangdong Microbial Culture Collection Center on January 30, 2026, and the preservation number is GDMCC No: 67775. Animal experiments prove that the strain can effectively colonize and remodel the intestinal flora homeostasis of high fat diet induced metabolic syndrome mice, and specifically promote the biosynthesis of intestinal endogenous spermidine. Based on the core function, the strain can significantly improve metabolic disorders of model mice, including reducing body weight, improving insulin resistance and sugar tolerance, regulating serum lipid mass spectrum and alleviating liver fatty degeneration and inflammatory injury. The invention protects the bacterial strain, a composition thereof, and application of the bacterial strain in preparation of products such as drugs and health foods for promoting synthesis of endogenous spermidine or improving metabolic syndrome.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.

This invention discloses a *Bifidobacterium longum* strain capable of regulating intestinal flora abundance and intestinal health, and its applications, belonging to the field of microbial technology. This invention screened a *Bifidobacterium longum* strain CCFM5871, which significantly increased the relative abundance of *Rikenobacterium* spp. in the mouse intestine, promoted the growth of *Bacteroides davidii*, improved intestinal health, and increased the lifespan of nematodes. The *Bifidobacterium longum* CCFM5871 described in this invention, which significantly increases the abundance of *Rikenobacterium* and *Rikenobacterium* spp. in the intestine and promotes the growth of *Bacteroides davidii*, has broad application prospects in food and microecological preparations.

The present application relates to the technical field of biotechnology, and aims to provide a Bacteroides uniformis with activity against porcine epidemic diarrhea virus and application thereof. The strain is preserved in China Center for Type Culture Collection, and the preservation name is Bacteroides uniformis ZJNB01, the Latin name is Bacteroides uniformis, and the preservation number is CCTCC NO: M 20241757. The porcine-derived Bacteroides uniformis has significant probiotic properties; due to rapid growth, it has strong resistance to porcine epidemic diarrhea virus. The Bacteroides uniformis and / or its metabolites can be used as a drug active center to produce a drug agent, and have a wide application scenario in the prevention and treatment of porcine epidemic diarrhea virus.

The invention belongs to the technical field of enteric microorganisms, and particularly relates to capsular polysaccharide derived from bacteroides sailli CSP6 as well as a preparation method and application of the capsular polysaccharide. The monosaccharide composition of the capsular polysaccharide mainly comprises fucose, glucose and glucosamine, the molecular weight is 7.139 * 10 < 5 > Da, the strain is stored in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M20221993. According to the present invention, the in vitro research results show that the capsular polysaccharide from the Bacteroides sailli CSP6 can provide the alpha-glycosidase inhibition effect; in-vivo animal experiments prove that the capsular polysaccharide can inhibit the increase of postprandial blood sugar and has the effect of reducing blood sugar.

The application discloses an adult depression intestinal microorganism marker and application thereof, and belongs to the field of biological medicine. The microorganism marker comprises one or more of the following: Clostridium aldrichii, Coprococcus comes, Klebsiella pneumoniae, Bifidobacterium adolescentis, Bacteroides vulgatus, Eubacterium eligens and Faecalibacterium prausnitzii. The application provides a product (such as a kit) comprising detection reagents for detecting the relative abundance of the microorganism marker. The product provided by the application has good feasibility and accuracy, and can effectively evaluate the risk of whether an adult has depression, thereby providing a new tool for clinical diagnosis.

The invention relates to application of common bacteroides in reducing blood sugar. Specifically, the invention provides a common bacteroides J2525 with a hypoglycemic function, the bacteroides is a gram-negative bacterium separated and purified from human excrement, the bacteroides is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, the preservation number is CGMCC NO.46398, the preservation number is CGMCC NO.46398, the preservation number is CGMCC NO.46398, and the preservation number is CGMCC NO.46398. The invention further provides a preparation method of the bacteroides J2525. The invention further provides a preparation method of the bacteroides J2525. The invention further provides a preparation method of the bacteroides J2525 with the hypoglycemic function and application of the bacteroides J2525 with the hypoglycemic function. The invention also provides application of the common bacteroides J2525 in preparation of products for reducing blood sugar, improving glucose tolerance or improving insulin sensitivity. The invention shows that the common bacteroid strain J2525 can be developed as a probiotic with a good hypoglycemic effect, and has a high reference value for clinical application of the strain.

The invention provides application of bacteroides faecalis as a target spot in detection and promotion of hot habit. Through systematic metagenomics analysis on excrement samples of hot-area crowds and warm-area control crowds and through difference comparison and verification research, the characteristic microbial marker bacteroides faecalis significantly related to the hot habit state is identified for the first time. The method can accurately reflect the adaptive state of an individual to the thermal environment, and can be used for non-invasive evaluation or auxiliary detection of the thermal habit degree. Based on the marker, the probability that an individual is in a hot habit state or a non-habit state can be quantitatively evaluated, and a new biomarker detection method is provided for objective diagnosis of hot habit.

The invention belongs to the technical field of enteric microorganisms, and particularly relates to application of bacteroides presl D2-16-sourced metabiotics in preparation of drugs and food for reducing postprandial blood sugar. And the bacteroides Zhangwenhongiii is a bacteroides Zhangwenhongiii D2-16, and the bacteroides Zhangwenhongiii is a bacteroides Zhangwenhongiii D2-16. The strain is separated from the intestinal tract of a healthy human body and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 20232720. The in-vitro research finds that the metagen from the bacteroides Zhang D2-16 can inhibit the activity of alpha-glycosidase; furthermore, in-vivo animal experiments prove that the metaplasm can inhibit the increase of postprandial blood sugar and has the effect of reducing blood sugar.

The invention discloses bacteroides ovatus and application thereof in degradation preparation of chondroitin sulfate oligosaccharide, and belongs to the technical field of microorganisms, the bacteroides ovatus JP2025813AP1 is preserved in China General Microbiological Culture Collection Center on December 05, 2025, and the preservation number is CGMCC No.46908. The invention further discloses a preparation method of the bacteroides ovatus JP2025813AP1 and application of the bacteroides ovatus JP2025813AP1 in degradation preparation of chondroitin sulfate oligosaccharide. The invention also provides an application of the bacteroides ovatus JP2025813AP1 in degradation and preparation of chondroitin sulfate oligosaccharide, and the bacteroides ovatus JP2025813AP1 can degrade chondroitin sulfate into unsaturated disaccharide. The invention also provides an application of the bacteroides ovatus JP2025813AP1 in degradation and preparation of the chondroitin sulfate oligosaccharide.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, CN or B7-2 inhibitor.

The invention discloses a common bacteroides efficiently utilizing 3 '-sialic acid lactose and application of the common bacteroides to improvement of intestinal health, the taxonomic name of the common bacteroides N059 is Phocaecola vulgaris, the common bacteroides N059 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, the preservation number is CGMCC No.46910, and the preservation date is December 11, 2025. The bacteroides vulgaris N059 disclosed by the invention can efficiently and specifically metabolize and utilize the 3 '-sialic acid lactose, has good probiotic characteristics, is suitable for being used as probiotics and prebiotics (such as the 3'-sialic acid lactose) for combined application, has better technical effects of improving intestinal health, relieving colitis and reducing enteritis-related inflammatory factors, and achieves the effects of regulating intestinal florae, improving intestinal health and improving intestinal health. The traditional Chinese medicine composition can be widely applied to animal breeding industry and related fields of food, medicines and the like.

The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide capable of improving animal intestinal health and resisting diarrhea and a preparation method thereof.The novel antibacterial peptide is prepared, and the amino acid sequence of the novel antibacterial peptide is shown as SEQ ID NO: 1; experiments prove that after the cat is raised in a strange environment for one week, the antibacterial peptide can slightly improve the propionic acid and butyric acid levels of the experimental group cat; and the total BCFAs level of the experimental group before and after transportation is lower than that of the blank group. Although the alpha diversity and the beta diversity between an experimental group fed with the antibacterial peptide and a blank group have no significant difference, the feeding of the antibacterial peptide significantly increases the levels of bacteroides, parabacteroides and paraprevotella in the experimental group, and significantly reduces the levels of harmful bacteria such as salmonella and actinomycetes. Therefore, the antibacterial peptide disclosed by the invention can be used for preparing products for improving animal intestinal health and resisting diarrhea, such as feed additives or oral liquid.